QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (74) Citing Articles via Google Scholar Google Scholar Articles by Wilson, J. M. Articles by Kish, S. J. Search for Related Content PubMed PubMed Citation Articles by Wilson, J. M. Articles by Kish, S. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB COCAINE DOPAMINE

 Previous Article  |  Next Article 

Volume 16, Number 10, Issue of May 15, 1996 pp. 3507-3510
Copyright ©1996 Society for Neuroscience

The Vesicular Monoamine Transporter, in Contrast to the Dopamine Transporter, Is Not Altered by Chronic Cocaine Self-Administration in the Rat

Received Jan. 23, 1996; revised Feb. 29, 1996; accepted March 4, 1996.

Julie M. Wilson and Stephen J. Kish

Human Neurochemical Pathology Laboratory, Clarke Institute of Psychiatry, Toronto, Ontario, Canada M5T 1R8

Although much evidence suggests that the brain dopamine transporter (DAT) is susceptible to dopaminergic regulation, only limited information is available for the vesicular monoamine transporter (VMAT2). In the present investigation, we used a chronic, unlimited-access, cocaine self-administration paradigm to determine whether brain levels of VMAT2, as estimated using [³H]dihydrotetrabenazine (DTBZ) binding, are altered by chronic exposure to a dopamine uptake blocker. Previously, we showed that striatal and nucleus accumbens DAT levels, as estimated by [³H]WIN 35,428 and [³H]GBR 12,935 binding, are altered markedly using this animal model (). However, in sequential sections from the same animals, [³H]DTBZ binding was normal throughout the entire rostrocaudal extent of the basal ganglia (including striatum and nucleus accumbens), cerebral cortex, and diencephalon, as well as in midbrain and brainstem monoamine cell body regions, both on the last day of cocaine access and after 3 weeks of drug withdrawal. These data provide additional evidence that VMAT2, unlike DAT, is resistant to dopaminergic regulation.

Key words: cocaine; vesicular monoamine transporter; dihydrotetrabenazine; quantitative autoradiography; self-administration; unlimited access

This article has been cited by other articles:

				C. S. Lee, M. Schulzer, R. de la Fuente-Fernandez, E. Mak, L. Kuramoto, V. Sossi, T. J. Ruth, D. B. Calne, and A. J. Stoessl Lack of Regional Selectivity During the Progression of Parkinson Disease: Implications for Pathogenesis Arch Neurol, December 1, 2004; 61(12): 1920 - 1925. [Abstract] [Full Text] [PDF]

				A. Moszczynska, P. Fitzmaurice, L. Ang, K. S. Kalasinsky, G. A. Schmunk, F. J. Peretti, S. S. Aiken, D. J. Wickham, and S. J. Kish Why is parkinsonism not a feature of human methamphetamine users? Brain, February 1, 2004; 127(2): 363 - 370. [Abstract] [Full Text] [PDF]

				K. Y. Little, D. M. Krolewski, L. Zhang, and B. J. Cassin Loss of Striatal Vesicular Monoamine Transporter Protein (VMAT2) in Human Cocaine Users Am J Psychiatry, January 1, 2003; 160(1): 47 - 55. [Abstract] [Full Text] [PDF]

				E. Kodas, S. Vancassel, B. Lejeune, D. Guilloteau, and S. Chalon Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage J. Lipid Res., August 1, 2002; 43(8): 1209 - 1219. [Abstract] [Full Text] [PDF]

				N. D. Volkow, L. Chang, G.-J. Wang, J. S. Fowler, D. Franceschi, M. Sedler, S. J. Gatley, E. Miller, R. Hitzemann, Y.-S. Ding, et al. Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence J. Neurosci., December 1, 2001; 21(23): 9414 - 9418. [Abstract] [Full Text] [PDF]

				J. M. Brown, G. R. Hanson, and A. E. Fleckenstein Regulation of the Vesicular Monoamine Transporter-2: A Novel Mechanism for Cocaine and Other Psychostimulants J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 762 - 767. [Abstract] [Full Text]

				S. M. N. EFANGE In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter FASEB J, December 1, 2000; 14(15): 2401 - 2413. [Abstract] [Full Text]

				J.-K. Zubieta, P. Huguelet, L. E. Ohl, R. A. Koeppe, M. R. Kilbourn, J. M. Carr, B. J. Giordani, and K. A. Frey High Vesicular Monoamine Transporter Binding in Asymptomatic Bipolar I Disorder: Sex Differences and Cognitive Correlates Am J Psychiatry, October 1, 2000; 157(10): 1619 - 1628. [Abstract] [Full Text]

				L. Zimmer, S. Delion-Vancassel, G. Durand, D. Guilloteau, S. Bodard, J.-C. Besnard, and S. Chalon Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n;-3 polyunsaturated fatty acids J. Lipid Res., January 1, 2000; 41(1): 32 - 40. [Abstract] [Full Text]

				K. Y. Little, L. Zhang, T. Desmond, K. A. Frey, G. W. Dalack, and B. J. Cassin Striatal Dopaminergic Abnormalities in Human Cocaine Users Am J Psychiatry, February 1, 1999; 156(2): 238 - 245. [Abstract] [Full Text]

				U. D. McCann, K. A. Lowe, and G. A. Ricaurte REVIEW {blacksquare} : Long-lasting Effects of Recreational Drugs of Abuse on the Central Nervous System Neuroscientist, November 1, 1997; 3(6): 399 - 411. [Abstract] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help